Search results

Sort By:

Limit search:

Non-pegylated liposomal doxorubicin based on treatment of diffuse large B-cell lymphoma in old patient with increased cardiovascular risk – case report and review of literature

100%

Joks M., Urbaniak M.

OncoReview

2018

vol. 8

issue 4

120-126

The use of anthracyclines in the treatment of patients with diffuse large B-cell lymphoma is crucial, however may be sometimes difficult or even contraindicated due to coexisting cardiovascular diseases. An alternative to conventional anthracyclines seems to be liposomal forms that have been registered in the first line of treatment for women with metastatic breast cancer. Data on their use in patients with non-Hodgkin’s lymphomas indicate high efficacy and acceptable toxicity. We present case report of treatment with immunochemotherapy using non-pegylated liposomal doxorubicin in elderly woman with diffuse large B-cell lymphoma coexisting with ischemic heart disease, hypertension, type 2 diabetes. In addition, we present review of literature and the aspects of the use of drugs off-label.

Off-label drug use in breast cancer therapy

100%

Jankowski T., Urbaniak M.

OncoReview

2017

vol. 7

issue 2

83-87

Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have undergone randomized clinical studies and have been registered for that specific indication. However, a number of drugs are used in an off-label manner, i.e. outside the officially approved product specifications. The paper discusses the use of several off-label therapies in breast cancer in order to demonstrate that such treatment may be well-grounded and indeed turns out beneficial in many cases. It describes the use of liposomal doxorubicin in pre- and post-operative treatment, capecitabine for incomplete efficacy of preoperative treatment, and the administration of metronomic vinorelbine. Moreover, the paper is aimed at demonstrating the legal basis and the principles of marketing authorization of off-label drug use.

Refine search results

2 OncoReview

1 2018

1 2017

2 Urbaniak M.

1 Jankowski T.

1 Joks M.

Search results

Non-pegylated liposomal doxorubicin based on treatment of diffuse large B-cell lymphoma in old patient with increased cardiovascular risk – case report and review of literature

Off-label drug use in breast cancer therapy